Formycon teams with Biocelys on FYB286, Santo funds the upfront costs
Formycon AG and Biocelys will develop the FYB286 biosimilar, with Santo Biosimilar GmbH funding the start and Formycon set to receive a revenue share.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Formycon AG has entered a partnership with Biocelys to advance FYB286, a biosimilar candidate. According to Formycon's press release distributed through EQS, Santo Biosimilar GmbH is covering the initial financing. In return, Formycon will receive market-rate payment and a revenue share in the low double digits from Santo's future sales of the product.
Biocelys will handle manufacturing, which secures GMP-grade production capacity.
why it matters
For Formycon, the deal eases cash needs and development risk, while recurring income depends on the drug reaching the market. The project is at an early stage, so clinical data and regulatory milestones will be the next key signals.
tags
instruments
sources
- Formycon AG (FYB) Partners With Biocelys on FYB286; Project Financed Upfront by Santo — eqs-news.com, 21 October 2026 at 04:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗